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Benjamin K. Hodnett and Peter Davern *
A new methanol solvate of clozapine base (CPB) has been identified. It exhibits different molecular ar-
rangements and bonding environments at low and room temperatures, while still maintaining the same
PXRD pattern throughout. Slurry experiments confirmed this CPB–MeOH solvate to be the thermodynami-
cally stable form in suspension relative to CPB. The CPB–MeOH solvate was further characterised using
TGA, DSC and VT-PXRD, with VT-PXRD confirming its conversion to CPB upon desolvation via heating. As
confirmed by PXRD, CPB–MeOH solvate was also crystallised heterogeneously from MeOH in the presence
of dextran (DEX), chitosan (CHT) and microcrystalline cellulose (MCC), with a significant reduction in induc-
tion time observed in the presence of all three excipients: 28, 18 and 15-fold in the presence of DEX, CHT,
and MCC respectively. The CPB–MeOH solvate crystals in the resultant composite solids were desolvated
to CPB upon heating to 120 °C for 6 h, causing their plate-like habit to deform to one containing pores
and ridges. The accompanying increase in crystal surface area led to a 3 to 5-fold increase in the extent of
CPB's dissolution from these desolvated CPB–MeOH crystals after 5 minutes and also after 1 h relative to
normal CPB crystals. Therefore, the potential may exist to enhance the dissolution rate of a poorly-soluble
active pharmaceutical ingredient (API), thereby improving its bioavailability, by crystallising it as a solvate in
the presence of an excipient heterosurface and thereafter desolvating the API crystals in the composite




Crystal engineering plays an important role in the process-
ing of pharmaceutical raw materials by improving material
attributes and possibly the efficacy of the final dosage
form.1 Particle engineering using excipients can improve
drug crystal habit, and thereby influence the packing,
flowability, compressibility, dissolution and sedimentation
properties of pharmaceutical powders.2 Different techniques
such as spherical agglomeration,1 spray drying,3 use of habit
modifiers,4 use of additives,5 or development of nano-
crystals6,7 are used to modify crystal habit. A number of ex-
amples in the literature demonstrate the effects of changing
crystal habit on in vitro dissolution rates, in order to im-
prove bioavailability.8,950
55Crystallisation, a complex process, is often treated as two
sequential steps, namely nucleation and crystal growth.10
Crystallisation from solution occurs with the solute mole-
cules undergoing molecular recognition, aggregation (con-
centration fluctuation) and pre-organisation processes in a
supersaturated solution, leading to the formation of hetero-
phases (nuclei) which act as centres of crystallisation.11 For-
eign substrates in contact with the supersaturated solution
can perform a significant role in heterogeneous primary
nucleation by lowering the free energy and/or increasing
the pre-exponential factor required for nucleation.12 In the
literature, a variety of surfaces such as polymers,13–16 self-
assembled monolayers,17 excipients,18,19 metallic sur-
faces,13,20 and surface coatings using organosilanes21,22 have
been widely studied as heterosurfaces to control nucleation.
In the pharmaceutical industry, there is an extensive ef-
fort to discover solid forms of drug substances that are opti-
mal for drug product development. Pharmaceutical solids
are generally classified as crystalline (ordered) or amor-
phous (non-ordered). Crystalline can be further sub-
classified as single component (polymorphs) and multi-





















30salts). Despite the existence of multiple crystalline forms
of individual active pharmaceutical ingredients (APIs), very
few forms possess physicochemical properties (e.g. process-
ability, stability and bioavailability) that are suitable for
formulation development.23 This has led to the use of
multi-component crystalline materials that exhibit desirable
physicochemical properties as potential API candidates. In-
deed, multi-component crystalline materials are the selected
solid form for a small number of commercial drug sub-
stances, e.g. cromolyn sodium (disodium cromoglycate,
nonstoichiometric hydrates)24 and nitrofurantoin (mono-
hydrate)25 as hydrates, and Entresto™ (monosodium
sacubitril, disodium valsartan and water)26 as a co-crystal.
Solid form screening also results in solvates, which tend to
be pharmaceutically unattractive due to the prevailing Inter-
national Conference on Harmonisation (ICH) guideline
limits on solvent content.27
The present work focuses on the crystallisation of an API
as a solvate in the presence of different heterosurfaces and
its related characterisation. It also examines the dissolution
rate of the API from a subsequently desolvated form of the
resultant composite solid. The heterosurfaces selected for
this work are widely used excipients in the pharmaceutical
industry and are approved by the US Food and Drug Admin-
istration (FDA). Excipients used were microcrystalline cellu-
lose (MCC), dextran (DEX) and chitosan (CHT) (Fig. 1). The
study was based on the hypotheses that (a) the nucleation
rate of the API would be enhanced in the presence of excipi-
ents, and (b) the dissolution rate of the API would be en-
hanced upon drying the crystallised API-solvate at a high
enough temperature to remove the solvent and thus create
structural defects. This general approach to API crystalliza-
tion could potentially streamline the processability of cer-2 | CrystEngComm, 2018, 00, 1–13
Fig. 1 Molecular structure of clozapine base (CPB) and the excipients usedtain APIs by avoiding the need for milling during formula-
tion, while also enhancing their bioavailability.
The model drug used for this particular work was cloza-
pine base (CPB), 8-chloro-11-(4-methylpiperazin-1-yl)-5H-
dibenzo-[b,e]ĳ1,4]diazepine (Fig. 1). CPB is described as an
atypical antipsychotic agent because it is effective in the
treatment of both positive and negative symptoms of schizo-
phrenia and has low extrapyramidal side effects.28 It has
been classified as class II by the Biopharmaceutical Classifi-
cation System due to its poor water solubility but good per-
meability.29 A comprehensive solid state and pharmacological
analysis of CPB has already been reported by McLeish et al.30
CPB exhibits one polymorph31 and one hydrate,31 as well as
dibromide,32 3,5-dinitrobenzoate,33 maleate33 and 2-hydroxy-
benzoate salts.33 Agnihotri et al.34 presented the controlled
release of CPB over 12 h from CPB-loaded chitosan micropar-
ticles of 543–698 μm size as compared with the fast dissolu-
tion of the as-received CPB over 4 h in phosphate buffer
solution of pH 7.4. Venkateshwarlu et al.35 reported the prep-
aration of solid lipid nanoparticles of CPB (mean size range
of 60–380 nm) with various triglycerides (trimyristin,
tripalmitin, tristearin), which exhibited a faster dissolution
rate in acidic medium than in deionized water. Zeng et al.36
reported that an orally disintegrating tablet formulation of
CPB exhibited faster dissolution than CPB (as-received) in
phosphate buffer solution of pH 6.8.
In light of the above, the scope of this paper is (i) to report
a new crystal structure for a CPB–MeOH solvate, (ii) to exam-
ine the heterogeneous nucleation of CPB–MeOH solvate in the
presence of DEX, CHT and MCC affording the respective API-
excipient composite solids, and (iii) to demonstrate how the
dissolution of CPB can be enhanced by desolvating the CPB–

































Methanol (MeOH, >99.9%), chitosan (MW: 50 000–190 000
Da) and dextran (MW: 35 000–45 000 Da) were supplied by
Sigma-Aldrich and used as-received. Microcrystalline cellu-
lose (MCC) (MW: 36 000 Da) was supplied by FMC Interna-
tional and was used as-received. Clozapine base (CPB, >98%)
was supplied by Novartis and used as-received (Fig. 1). The
powder X-ray diffraction (PXRD) pattern of the as-received
CPB confirmed it to be the orthorhombic polymorph (CCDC
NDNHCL10).
2.2. Solubility of CPB in MeOH
The solubility of CPB in MeOH was measured using the gravi-
metric method37 in the range 5 °C to 30 °C, and the experi-
mental set up was consistent with the method reported by
Cheuk et al.38 The same method was applied to measure the
solubility of CPB–MeOH solvate in methanol.
2.3. Crystallization of CPB from MeOH in the absence and
presence of excipients
The crystallization of CPB in the absence and presence of ex-
cipients was performed at a 600 mL scale in a 1 L LabMax au-
tomated reactor (Mettler Toledo). Nucleation and %-
desupersaturation were monitored in situ via ATR-FTIR (iC10
(Mettler Toledo)) in conjunction with iControl LabMax soft-
ware (Mettler Toledo). The crystallization proceeded under
isothermal conditions following the cooling of saturated solu-
tions of CPB in MeOH at, for example, 25 °C (CPB solubility
= 80.9 g kg−1 methanol) to a crystallization temperature of 15
°C (CPB solubility = 68.6 g kg−1 methanol) which generated a
supersaturation ratio (S) of 1.18. For those crystallizations
performed in the presence of excipients, the amount of excip-
ient added was such that a maximum attainable CPB loading
of 25% w/w would be achieved assuming complete
desupersaturation of the CPB–MeOH metastable solutions, as
defined in eqn (1).
(1)
Similar crystallisation experiments were also done at
supersaturations of 1.08 and 1.28 to examine the effect of
supersaturation on the crystallisation of CPB from methanol
solution.
2.4. Single crystal growth experiment
Single crystals of the methanol solvate of clozapine base
(CPB–MeOH solvate) were prepared by transferring a cloza-
pine–MeOH solution saturated at 25 °C (equilibrated for at
least 24 h in advance) to a water-bath set at 15 °C, creating
a supersaturation of 1.18. The resultant slurry was filteredThis journal is © The Royal Society of Chemistry 2018and the solid obtained was characterised as described in
section 2.5.2.5. Solid state characterization of CPB–MeOH solvate
2.5.1. Single crystal X-ray diffraction (SCXRD). Single-crys-
tal X-ray diffraction (SCXRD) measurements were collected at
27 °C (room temperature) and at −173.15 °C, on a Bruker
Quest D8 Mo sealed tube (λ = 0.71073 Å), equipped with
CMOS photon detector. Data were corrected for absorption
using empirical methods (SADABS) based upon symmetry-
equivalent reflections combined with measurements at differ-
ent azimuthal angles. Crystal structures were solved and re-
fined against all F2 values using the SHELX interfaced with
the X-SEED program. Non-hydrogen atoms were refined an-
isotropically and hydrogen atoms were placed in calculated
positions refined using idealized geometries (riding model)
and assigned fixed isotropic displacement parameters. The
crystallographic information files (CIF) are available from the
CCDC (deposition numbers 1583624 and 1583625).
2.5.2. Powder X-ray diffraction (PXRD). Powder X-ray
diffractograms (PXRDs) were recorded on a PANalytical Em-
pyrean diffractometer using a Cu radiation source (λ = 1.541
nm) at 40 mA and 40 kV. Scans were performed between 5
and 35° 2θ at a scan rate of 0.013° 2θ min−1.
2.5.3. Variable temperature powder X-ray diffraction
(VT-PXRD). Variable temperature powder X-ray diffraction
(VT-PXRD) was carried using a PANalytical X'per MPD Pro
with Cu source (λ = 1.541 nm) at 40 mA and 40 kV and
equipped with an Anton-Paar TK 450 hot stage. The sample
was scanned from 4° to 45° (2θ) with a scan step size of 0.033°
(2θ) and 30 s per step. Scans were carried out between 30 °C
and 150 °C under a nitrogen atmosphere; diffractograms were
collected at pre-determined temperatures.
2.5.4. Scanning Electron microscopy. The habit of the iso-
lated particles was examined by SEM (JCM-5700 (JEOL)). Sam-
ples were gold coated (S150B, Edward) and the surface ap-
pearances of the as-received DEX, CHT, MCC and the
isolated CPB-excipient composite solids were compared. SEM
micrographs were also used to measure the crystal size of
CPB, CPB–MeOH solvate and desolvated CPB.
2.5.5. Thermogravimetric analysis (TGA). Thermogravi-
metric analysis (TGA) was carried out under a nitrogen atmo-
sphere (50 mL min−1) using a PerkinElmer TGA 4000 instru-
ment. Experiments were carried out using alumina crucibles
at a temperature ramp of 20 °C min−1 from 30 °C to 550 °C.
TGA data were analysed using Pyris 6 software version
11.1.10492.
2.5.6. Differential scanning calorimetry (DSC). Differential
scanning calorimetry (DSC) was carried out under a nitrogen
atmosphere (30 mL min−1) in the temperature range 30–240
°C at a ramp rate of 20 °C min−1 using a PerkinElmer Pyris 1
DSC instrument. Experiments were carried out using plati-
num pans with pinholes (as manufactured) and sealed by a
crimping press. The instrument was calibrated using indium


















202.6. In vitro drug release studies
The dissolution of API-excipient composite powder samples
(which had been previously desolvated by heating to 120 °C
for 6 h) was performed under sink conditions with a maxi-
mum CPB solution concentration, [CPB]max, of 4.25 mg L
−1
(versus the corresponding equilibrium solubility, [CPB]eq., of
13 mg L−1) in de-ionised water (1000 mL). The agitation
speed was set to 150 rpm using a magnetic stirrer and the
temperature of the dissolution medium was maintained at 37
± 1 °C. Aliquots (1 mL) were withdrawn at predetermined
time intervals (1, 3, 5, 10, 15, 30, 45 and 60 min) and were fil-
tered by Whatman Nylon 13 mm filters of 0.2 μm pore size
before being analysed by UV spectrophotometry. The CPB ab-
sorption maximum (λmax = 292 nm, ε = 12 208 mol
−1 L cm−1
(comparable with the reported value of 10 000 mol−1 L cm−1
at 296 nm (ref. 30))) was used to quantify the amount of CPB
dissolved. For the purposes of comparison, the above dissolu-
tion experiment was also performed on the following: (i)
CPB, and (ii) CPB physically mixed with each of the three ex-
cipients, whereby each dissolution sample comprised a ‘phys-
ical mix’ of CPB (25% w/w) and the relevant excipient.25
3. Results and discussion
3.1. Solubility of CPB in methanol at various temperatures
The solubility of CPB was determined in methanol from 5 °C
to 30 °C at ca. 5 °C intervals under atmospheric pressure.4 | CrystEngComm, 2018, 00, 1–13
Fig. 2 Solubility curve of CPB (blue diamonds) and CPB–MeOH solvate (r
best fit lines.The solubility of CPB as a function of temperature is shown
in Fig. 2. The solid phase in equilibrium with the solution
for these experiments was confirmed by PXRD to be CPB.3.2. Isolation and solid state characterisation of a new solid
form
The induction time for the crystallization of clozapine was
measured in methanol at a supersaturation (S) of 1.18 (S = c/c*;
where c = the solubility at the saturation temperature, and
c* = the solubility at the crystallisation temperature) as a pre-
requisite for the heterogeneous nucleation experiments
performed in the presence of solid excipients. During these
induction time experiments, the solid form crystallising from
the CPB–MeOH solutions was neither the single known poly-
morph of this material nor any other known form (Fig. 3).31
As reported by Bajpai et al.,39 molecules that possess no hy-
drogen bond donor groups and only possess hydrogen bond
acceptor groups demonstrate a greater propensity to form
hydrates. CPB has four hydrogen bond acceptor groups and
only one hydrogen bond donor group, meaning that it might
form hydrates. However, under the prevailing experimental
conditions of this study, CPB hydrate formation is unlikely
due to the very low levels (if any) of water present in the
methanol used.
TGA analysis was performed on this new solid form
(Fig. 4). The TGA thermogram of the unknown solid
presented a weight loss of nearly 8.9% in the temperatureThis journal is © The Royal Society of Chemistry 2018







Fig. 3 Comparative PXRD patterns of CPB (red, CCDC NDNHCL10),























range of 85–125 °C, which is the typical temperature range
for methanol expulsion from the solid. This suggested thatThis journal is © The Royal Society of Chemistry 2018
Fig. 4 TGA and DSC (insert) analysis of CPB as-received (red) and CPB–Methe unidentified solid might be a CPB–MeOH solvate. The
recorded weight loss is consistent with a CPB :methanol
stoichiometric ratio of 1 : 1. DSC thermograms of the un-
known solid also exhibited an endothermic peak at 84.5 °C
with peak onset at 78.5 °C, also suggesting it to be a CPB–
MeOH solvate, followed by a CPB melting peak at 186.15 °C
(Fig. 4).
Single crystals of this new methanol solvate were then
grown from methanolic solutions, using the same supersat-
uration and cooling conditions from the aforementioned in-
duction time experiments. Interestingly, the solvate could
not be grown by solvent evaporation in methanol, where
CPB was found to preferentially crystallise. Once the CPB–
MeOH crystals were grown, the single crystal structure of
the solvate was obtained at room temperature (RT, 10 to 30
°C) and low temperature (LT, −173.15 °C) (Table 1). In both
the room temperature and low temperature solvate struc-
tures, the methanol molecules displayed positional disorder.
At low temperature, −173.15 °C, the oxygen molecule of
methanol appears in two different positions, while the car-
bon of the methyl group remains fixed. Conversely, at room
temperature (∼27 °C) the opposite occurs, and the oxygen
atom of methanol appears fixed while the carbon atom ap-
pears disordered. From the single crystal structure obtained
at −173.15 °C the disorder in the structure indicated that
the methanolic oxygen atom can be involved in one of two
separate hydrogen bonding interactions, and the hydrogen
bond that methanol forms in this structure depends on the
position of the oxygen atom within the lattice. In the struc-
ture obtained at −173.15 °C, O–H–N bonding occurs be-
tween the oxygen of methanol and the imine nitrogen of
the seven-membered ring on clozapine (2.818 Å, present in
40% of the reflections observed during the single crystal ex-
periments) or between the oxygen of methanol and the






Table 1 Summary of the crystallographic data obtained from SCXRD for
the CPB–MeOH solvate at room temperature (RT) and low temperature






Crystal system Orthorhombic Monoclinic Monoclinic
Space group P212121 C2/c C2/c
Ref. 31 This work This work
Description Blocks Plates Plates
a, Å 18.04(3) 20.275(2) 20.0103(8)
b, Å 9.57(1) 10.7573Ĳ11) 10.5732(5)
c, Å 9.50(1) 17.3839Ĳ17) 17.3750(8)
α, deg 90 90 90
β, deg 90 95.541(2) 96.1720Ĳ10)
γ, deg 90 90 90
Volume, Å3 1640.11 3773.79 3654.77
Dcal, g cm
−3 1.324 1.263 1.304
Dexp, g cm
−3 1.32
R-factor (%) 3.6 9.79 6.3
Temp (°C) 10–30 10–30 −173.15
Fig. 5 Comparison of the unit cells of the CPB–MeOH solvate at


























55(2.867 Å, present in 60% of the reflections), Fig. 5. At 27 °C,
the position of methanol's oxygen atom in the crystal was
fixed, but disorder appeared in the carbon atom of its
methyl group. The oxygen atom of methanol uniformly hy-
drogen bonded with the same imine nitrogen of the seven-
membered ring on clozapine, while the position of the car-
bon atom fluctuated, Fig. 5. This disorder of the methanol
molecule in the solvate is likely the result of weak O–H–N
bond formation between methanol and clozapine. Indeed it
was noticed that upon isolating solvated crystals from meth-
anol solution, the transparent crystals would turn cloudy
within 20–30 minutes at room temperature, indicating a
loss of solvent. The subtle changes in bonding environment
of the clozapine solvate at the different temperatures,
highlighted here, are likely due to a disorder–disorder tran-
sition occurring between −173.15 °C and 27 °C.
Despite different molecular arrangements in the CPB–
MeOH solvate lattices at low and room temperatures, the
PXRD patterns for both structures are similar with peaks of
the low temperature structure shifted to a higher 2θ values
by 0.11 degrees compared with those of the room tempera-
ture structure, as shown in Fig. 6. This shift is due to the
shrinkage of the crystal lattice at the lower temperature
which decreases the d-spacing resulting in larger values
of 2θ.
VT-PXRD data presented in Fig. 7 confirmed that MeOH
leaves the CPB–MeOH crystal lattice between 80 °C and 90
°C to afford CPB which persists during cooling to room
temperature. This conversion was confirmed by the disap-
pearance of the (200) peak of the solvate at 8.76° 2θ and
the appearance of the confirmatory (101) peak of CPB at
10.49° 2θ.31
CPB–MeOH solutions saturated at 25 °C (S = 1) were
slurried with a 50 : 50 mixture of CPB–MeOH solvate and
CPB. All the solids in the slurry were converted to CPB–
MeOH solvate after two days, as confirmed by PXRD. The6 | CrystEngComm, 2018, 00, 1–13solubility of CPB–MeOH solvate in methanol was measured
at different temperatures between 10 and 25 °C and was
compared with the solubility of CPB in methanol (Fig. 2)
over the same temperature range. The solubility of CPB–
MeOH solvate in methanol was found to be 1.3 to 1.1 times
lower than the corresponding solubility of CPB as the tem-
perature increased from 10 to 25 °C, respectively. The solid
phase in equilibrium with the solution phase at the equili-
bration temperature was confirmed by PXRD to be CPB–
MeOH solvate. Thus CPB–MeOH solvate is the thermody-
namically stable form relative to CPB in methanolic suspen-
sions at 25 °C or less.3.3. Crystallisation of CPB in the absence and presence of
excipients
3.3.1. Effect of excipients. Fig. 8 illustrates the change in
the induction time and the rate of desupersaturation in
terms of the solution concentration of CPB (via in-situ FTIR)This journal is © The Royal Society of Chemistry 2018
Fig. 6 Calculated PXRDs for CPB (red, CCDC NDNHCL10), CPB–MeOH solvate at low temperature (olive green), and CPB–MeOH solvate at room
temperature (blue); and the experimentally determined PXRD for CPB–MeOH solvate (brown); the highlighted region between 8 and 12° 2θ is

























55in the absence and presence of dispersed excipients at 15 °C
(equivalent to a supersaturation of 1.18).
In the absence of excipients, an induction time of ca.
510 min was observed for the CPB–MeOH solution; this re-
duced to ca. 36, 30, 20 min in the presence of dispersed
MCC, CHT and DEX respectively as summarised in
Table 2. According to eqn (2) (ref. 40) below, these reduc-
tions correspond to nucleation rates for CPB that were 15,
18 and 28 times greater in the presence of MCC, CHT and




J = nucleation rate (nuclei m−3 s−1).
tind = induction time (s).
V = volume (m3).
These reductions in the induction time of CPB in the
presence of excipients are significantly larger than those ob-
served during the crystallisation of carbamazepine (CBMZ)This journal is © The Royal Society of Chemistry 2018or paracetamol (AAP) in the presence of MCC, previously
reported.18,41 In the case of CPB, as confirmed by PXRD
(Fig. 10), CPB–MeOH solvate crystallised in the presence of
each of the three excipients; and as supported by single
crystal data (Fig. 5), methanol forms a hydrogen bond with
one of the hydrogen bond acceptors (the imine nitrogen) in
CPB leaving all other hydrogen bond acceptor moieties free
to form a hydrogen bond with the hydroxyl (–OH) groups
on either the excipient surface or the methanol solvent
molecules. Reports in the literature suggest that the average
lifetime of the interaction between a molecule in solution
and a solid surface is longer than the corresponding aver-
age lifetime of the interaction between two molecules in
solution.42–46 The duration of such average lifetimes varies
depending on whether the interactions are specific or non-
specific. As such, the lifetime of van der Waals (non-spe-
cific) interactions between molecules in solution is of the
order of 0.8 to 3 ps,43 whereas the corresponding range for
a hydrogen bond (specific) is 1 to 70 ps.44 The correspond-
ing range for a hydrogen bond between a molecule in solu-
tion and a solid surface is of the order of 1 to 160 ns.45 In
this context, the general time frame for the formation of
an API nucleus is in the region of 100 to 1000 ns.46 AnCrystEngComm, 2018, 00, 1–13 | 7
Fig. 7 As displayed from the bottom upwards, VT-PXRDs for CPB–
MeOH solvate at 30, 50, 70, 80, 90 and 100 °C, and CPB (red).
Table 2 Induction time (min) and nucleation rate (nuclei m−3 s−1) of
CPB–MeOH solvate during its crystallization from MeOH solution (S =











MCC 36 ± 10 0.77 15
CHT 30 ± 5 0.92 18





















30understanding of these various interaction lifetimes sug-
gests that the hydrogen bond formed between a CPB mole-8 | CrystEngComm, 2018, 00, 1–13
Fig. 8 %-Desupersaturation of CPB–MeOH solution in the absence
and presence of excipients (MCC, DEX and CHT) at S = 1.18. Note: the
horizontal axis has been abridged between ca. 120 and 450 minutes to






55cule and the hydroxyl group on an excipient surface can
last long enough to allow the formation of a CPB–MeOH
nucleus on the excipient surface thereby facilitating hetero-
geneous nucleation. Thus, hydrogen bond complementarity
between the CPB–MeOH and the excipient surface facili-
tates the sequestering of a CPB–MeOH cluster onto the
excipient surface leading to an increase in the pre-
exponential factor, thus reducing the induction time and
increasing the nucleation rate. Furthermore the extent to
which this sequestering of a CPB–MeOH cluster onto the
excipient surface occurred was in the order of DEX > CHT
> MCC, as reflected by their respective nucleation rate
ratios ( Jhet/Jhom) of 28, 18 and 15. Even though all the
excipients possess hydroxyl (–OH) groups on their surface
capable of providing complementarity to a nascent CPB–
MeOH cluster, DEX exhibited the greatest reduction in
induction time. This may be due to the spherical habit of
its particles versus the somewhat irregular shape of CHT
and MCC's particles. In this regard, Quon et al.47 attributed
a similar increase in acetaminophen's nucleation rate in
the presence of spherical agglomerates of lactose (versus
the rate in the presence of single crystal lactose) to the
ability of the spherical particles to promote improved geo-
metric lattice matching and molecular complementarity.
3.3.2. Effect of Supersaturation. Table 3 summarises the
effect of varying supersaturation on induction times and nu-
cleation rates during the crystallization of CPB–MeOH solvate
from MeOH solution in the absence and presence of MCC.
This excipient was selected for this study due to its ease of
use, its ready availability and its widespread use in pharma-
ceutical formulation; additionally it displays favourable com-
pressibility properties, as was shown in an earlier study from
our group.41 PXRD analysis confirmed that CPB–MeOH crys-
tals nucleated in the absence and presence of MCC at all
supersaturations studied.
The dependence of nucleation rate on supersaturation
can be seen in Table 3, where lower supersaturations afford
lower nucleation rates and vice versa. The data were analysed
using the nucleation rate equation (eqn (3)) published by
Kashchiev et al.12
J(S) = AS exp(−B/ln2 S) (3)This journal is © The Royal Society of Chemistry 2018
Fig. 9 A plot of ‘lnĲJ/S) or lnĲJ*/S)’ against (1/(T3ln2 S)) × 106 that illustrates the dependence of nucleation rate on supersaturation for the
crystallization of CPB–MeOH solvate from MeOH in the absence (blue diamond) and presence (red square) of MCC at different supersaturations;





















J = Nucleation rate (nuclei m−3 s−1); JĲS) implies the nucle-
ation rate at a given supersaturation, S








v0 = Molecular volume (m
3) (for CPB: 4.1 × 10−28 m3)
γef = Interfacial energy of the cluster/solution interface, for
heterogeneous nucleation (J m−2)
k = Boltzmann constant (J K−1) (1.38 × 10−23 J K−1)
T = Crystallization temperature (K).
Eqn (3) can be re-written as follows:
ln( J/S) = lnA − (B/ln2 S)
The dependence of nucleation rate on supersaturation in
the absence and presence of MCC at three different super-
saturations (1.08, 1.18 and 1.28) is presented in Fig. 9. Best
fit linear equations were used to calculate the interfacial en-
ergy (γ) and the pre-exponential factor (A) in the absence
and presence of MCC. The interfacial energies calculated in
the absence and presence of MCC are 0.58 and 0.54 mJ m−2
respectively. According to the Classical Nucleation Theory
(CNT), nucleation rate is defined as:55
J = A exp(−ΔGcrit/RT) (4)
where,This journal is © The Royal Society of Chemistry 2018ΔGcrit = Free energy/activation energy required for nucle-







The comparable interfacial energies calculated for CPB–
MeOH solvate to crystallise in the absence and presence of
MCC signify that the activation energy required for nucle-
ation in both crystallisation systems is relatively similar be-
cause activation energy depends on interfacial energy at a
given supersaturation. For example, the activation energies
required for nucleation at S = 1.18 in the absence and pres-
ence of MCC are 1.02 × 10−21 J and 1.25 × 10−21 J, respectively.
However, despite these similar activation energies, the induc-
tion time of CPB–MeOH solvate is significantly lower in the
presence of MCC than in its absence. This signifies an in-
crease in the pre-exponential factor for the crystallization of
CPB–MeOH solvate in the presence of MCC (A = 1.36 m−3 s−1)
relative to same crystallization in its absence (A = 0.075 m−3
s−1). From this it can be concluded that the heterogeneous
nucleation of CPB–MeOH solvate occurs due to the provision
of extra nucleating sites in the form of a heterosurface, and
not due to a significant change in the activation energy re-
quired for nucleation.3.4. Solid state characterisation of the isolated solids in the
presence of excipients
Fig. 10 presents the PXRD patterns of the CPB-excipient com-
posite solids isolated after 100% desupersaturation of a CPB–
MeOH solution in the presence of each of the threeCrystEngComm, 2018, 00, 1–13 | 9
Fig. 10 PXRD patterns of the composite solids isolated after complete desupersaturation of a CPB–MeOH solution in the presence of CHT (left),
DEX (middle) and MCC (right), at Tcry = 15 °C and S = 1.18; 25% w/w loading of CPB–MeOH solvate.
Table 3 Summary of the induction times for the crystallization of CPB–MeOH solvate from methanol at various supersaturations in the absence and




















1.08 20 1020 0.03 70 0.4 15
1.18 15 510 0.05 36 0.77 14
1.28 10 256 0.11 12 2.31 21

























55excipients, confirming the crystallisation of CPB–MeOH sol-
vate in the presence of all three excipients. This is the first
reported heterogeneous nucleation of a solvate. The (111),
(112̄) and (112) peaks at 10.8°, 13.25° and 14.13° 2θ respec-
tively, are the confirmatory peaks of CPB–MeOH solvate in
the presence of the different excipients.
Fig. 11 presents the SEM micrographs of CPB–MeOH sol-
vate crystallised in the presence of each of the three excipi-
ents. Plate-like crystals of the solvate were observed to be
well-adhered to the excipient surface in all cases. It is possi-
ble that these composite solids containing CPB-solvate crys-
tals could have formed during the filtration process or via
the agglomeration of particles in the slurry. However, such
crystals would likely exhibit well-defined edges in all dimen-
sions, which is not observed in Fig. 11. Instead, the observed
adherence of the CPB-solvate crystals to the excipient surface
is accompanied by a characteristic interface (highlighted by
the dashed red ellipses) which may have occurred via the
heterogeneous nucleation and subsequent growth of the sol-
vate crystals on the excipient surface. Fig. 11 also presents
the SEM micrographs of the isolated solids after complete10 | CrystEngComm, 2018, 00, 1–13desupersaturation of the CPB–MeOH solution in the presence
of excipients followed by heating to 120 °C for 6 h. The plate-
like habit of the CPB–MeOH solvate crystals was transformed
to one containing pores or ridges; this is likely due to the
progressive evacuation of methanol solvent through the inter-
layer planes or channels at high temperature, which appears
to have occurred without unduly compromising the crystallin-
ity. This type of transformation proceeding throughout the
crystal volume is known as a topotactic transition.48 As such,
a topotactic transition involves the retention of similar three
dimensional states following the transformation between two
polymorphic forms, in this case the transformation between
the solvated and desolvated CPB crystal. This transition was
also confirmed using VT-PXRD (Fig. 7), as the diffraction pat-
tern of solvated CPB–MeOH transforms to that of CPB.3.5. Dissolution of de-solvated CPB–MeOH crystals
crystallised in the presence of excipients
In general terms, reducing the particle size or increasing the
specific surface area leads to an increase in dissolutionThis journal is © The Royal Society of Chemistry 2018
Fig. 11 SEM micrographs of CPB–MeOH solvate crystallised in the presence of the three excipients at a supersaturation of 1.2 before (left) and

























55rate.41 This effect was observed on comparing the dissolution
rates of desolvated CPB–MeOH crystals crystallised in the
presence of excipients with that of CPB crystals. As presented
in Fig. 12, the extent of the dissolution of desolvated CPB–
MeOH crystals from the corresponding API-excipient compos-
ite solids was ca. 3 to 5-fold greater after 5 minutes and also
after 1 hour than that observed for CPB, and was ca. 2 to
3-fold greater than that observed for the three CPB-excipient
‘physical mix’ samples. This enhanced dissolution of the
desolvated CPB–MeOH crystals is likely due to the increase in
their surface area that occurred during the high temperature
desolvation process, as opposed to being just an artefact of
their particle size because the crystal size distributions for
CPB in the normal crystals, the ‘physical mix’ samples and
the desolvated crystals are comparable.This journal is © The Royal Society of Chemistry 20184. Conclusions
A new MeOH solvate of CPB has been identified using
SCXRD. Different molecular arrangements and bonding envi-
ronments were observed for this CPB–MeOH solvate at low
and room temperatures but these did not change the PXRD
pattern. CPB–MeOH solvate is the thermodynamically stable
form in suspension relative to CPB, as confirmed by slurry ex-
periments. The CPB–MeOH solvate was further characterised
using TGA, DSC and VT-PXRD, with VT-PXRD confirming its
conversion to CPB upon heat-induced desolvation. The CPB–
MeOH solvate crystallised heterogeneously from MeOH in
the presence of DEX, CHT and MCC, as confirmed using
PXRD. During these crystallizations, a significant reduction
in induction time was observed in the presence of all threeCrystEngComm, 2018, 00, 1–13 | 11
Fig. 12 The dissolution profiles of (i) CPB (blue diamonds), (ii) de-solvated CPB–MeOH crystals from the following API-excipient composite solid
samples: DEX (red square), CHT (green triangles) and MCC (violet circles), and (iii) ‘physical mix’ samples of CPB (25% w/w) with DEX (plus sign),
CHT (orange circle) and MCC (blue star). Dissolution conditions: de-ionised water, pH 7, 37 ± 1 °C, 150 rpm, [CPB]max = 4.25 mg L
−1 versus [CPB]eq.


























55excipients: 28, 18 and 15-fold in the presence of DEX, CHT
and MCC respectively. The plate-like habit of the CPB–MeOH
solvate crystals formed in the presence of all three excipients
was deformed to one containing pores and ridges in the
desolvated CPB–MeOH crystals produced upon heating the
isolated composite solids to 120 °C for 6 h. These pores and
ridges increased the available surface area for dissolution,
thus leading to a ca. 3 to 5-fold increase in the extent of dis-
solution of the desolvated CPB–MeOH crystals relative to nor-
mal CPB crystals after 5 minutes and also after 1 h. There-
fore, the dissolution rate of a poorly-soluble API could be
improved, thus improving its bioavailability, by crystallising
it as a solvate in the presence of an excipient heterosurface
and thereafter desolvating the API crystals in the composite
solid at elevated temperature. Such API crystals, with their
increased surface area and now being attached to an excipi-
ent particle, could potentially be tabletted directly with
greater compactability and flowability, thus avoiding the
need for milling during the downstream formulation of the
drug product.
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